| Application no. and date | 17191721.4 (espacenet) (Federated) (European Patent Register), 20120514 | | Patent/reg. no. and date | DK/EP 3275892, 20200108 | | Publication date | 20180131 | | Priority no. and date | US 201161486005 P, 20110513 | | EP pub. no. and date |
EP 3275892 20180131 | | Effective date | | | Applicant/owner | GlaxoSmithKline Biologicals S.A., Rue de l'Institut, 89
1330 Rixensart, BE | | Applicant ref. no. | 163455 | | Inventor | SWANSON, Kurt, c/o Novartis Vaccines And Diagnostics, Inc.
P.O. Box 8097
Emeryville, CA 94662-8097, US,
CARFI, Andrea, c/o Novatis Vaccines And Diagnostics, Inc.
P.O. Box 8097
Emeryville, CA 94662-8097, US | | Representative | AWA Denmark A/S, Strandgade 56, 1401 København K, DK | | Opponent | | | IPC Class | C07K 14/135 (2006.01) | | Title | PRÆFUSIONS-RSV-F-ANTIGENER | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | | | Status | Ophævet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
